ABVC BioPharmaABVC +10.00%17 Debt-to-Equity is 0.25 as of Mar. 2026, which is 19% below its 10-year median of 0.31. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 964 Biotechnology companies, ABVC BioPharma ranks worse than 59.44% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for ABVC BioPharma's Debt-to-Equity or its related term are showing as below:
ABVC'
s Debt-to-Equity Range Over the Past 10 Years
Min: -30.33 Med: 0.31 Max: 6.21
Current: 0.25
During the past 13 years, the highest Debt-to-Equity Ratio of ABVC BioPharma was 6.21. The lowest was -30.33. And the median was 0.31.
ABVC's Debt-to-Equity is ranked worse than 59.44% of 964
companies
in the Biotechnology industry
Industry Median: 0.16
vs ABVC: 0.25
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
ABVC BioPharma Debt-to-Equity Related Terms
ABVC BioPharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for ABVC BioPharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABVC vs GRCE, ELOX, INMB: Debt-to-Equity Comparison
For the Biotechnology subindustry, ABVC BioPharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABVC BioPharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ABVC BioPharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where ABVC BioPharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABVC BioPharma (ABVC) has a Debt-to-Equity of 0.25 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ABVC BioPharma and its competitors. This is 19% below median its historical median of 0.31. According to the industry distribution chart, ABVC BioPharma ranks #573 out of 964 companies in the Biotechnology industry, placing it in the top 59.4%.
Is ABVC BioPharma's Debt-to-Equity too high?
ABVC BioPharma's current Debt-to-Equity of 0.25 is 19% below median its 10-year median of 0.31. The Biotechnology industry median Debt-to-Equity is 0.16. ABVC BioPharma's value of 0.25 is 56.3% above this industry median. Based on the distribution chart, ABVC BioPharma ranks #573 out of 964 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's Debt-to-Equity compare to GRCE and ELOX?
According to the Biotechnology industry distribution chart, ABVC BioPharma ranks #573 out of 964 companies for Debt-to-Equity. This places ABVC BioPharma in the lower half of its industry. The industry median Debt-to-Equity is 0.16. ABVC BioPharma's value of 0.25 is 56.3% above this benchmark. While the company's 10-year median is 0.31 vs. the industry median of 0.16, ABVC BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABVC BioPharma's current Debt-to-Equity of 0.25 is 56.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ABVC BioPharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABVC BioPharma's current Debt-to-Equity is 0.25, which is 19% below median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $2.09 — trading 140.2% above its estimated fair value. The current Debt-to-Equity is 0.25, which is 19% below median its 10-year median of 0.31 and 56.3% above the Biotechnology industry median of 0.16. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current Debt-to-Equity is 0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABVC BioPharma (ABVC) Overvalued in 2026?
Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued.
The current stock price of $2.09 is trading 140.2% above its estimated GF Value™ of $0.87.
GuruFocus considers ABVC BioPharma to be Significantly Overvalued.
Key valuation signals for ABVC:
Debt-to-Equity: 0.25 (19% below median its 10-year median of 0.31)
GF Value™: $0.87 vs. price of $2.09 (140.2% above fair value)
Industry Position: 56.3% above the Biotechnology median (#573 of 964)
No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score
Get the complete analysis for ABVC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABVC has been successfully added to your 
